Abstract
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | European Journal of Obstetrics & Gynecology and Reproductive Biology |
| Vol/bind | 144 |
| Udgave nummer | 1 |
| Sider (fra-til) | 48-53 |
| Antal sider | 6 |
| ISSN | 0301-2115 |
| DOI | |
| Status | Udgivet - 1 maj 2009 |
Bibliografisk note
Keywords: Adult; Aromatase Inhibitors; CA-125 Antigen; Down-Regulation; Drug Therapy, Combination; Endometriosis; Estrogens; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone; Goserelin; Humans; Nitriles; Pilot Projects; Pregnancy; Pregnancy Outcome; Prospective Studies; Triazoles; Uterine DiseasesAdgang til dokumentet
Citationsformater
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Combined down-regulation by aromatase inhibitor and GnRH-agonist in IVF patients with endometriomas-A pilot study. / Lossl, Kristine; Loft, Anne; Freiesleben, Nina L C; Bangsbøll, Susanne; Andersen, Claus Yding; Pedersen, Anette T; Hartwell, Dorthe; Andersen, Anders Nyboe; Løssl, Kristine; Loft, Anne; Freiesleben, Nina L C; Bangsbøll, Susanne; Andersen, Claus Yding; Pedersen, Anette T; Hartwell, Dorthe; Andersen, Anders Nyboe.
I: European Journal of Obstetrics & Gynecology and Reproductive Biology, Bind 144, Nr. 1, 01.05.2009, s. 48-53.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
}
TY - JOUR
T1 - Combined down-regulation by aromatase inhibitor and GnRH-agonist in IVF patients with endometriomas-A pilot study
AU - Lossl, Kristine
AU - Loft, Anne
AU - Freiesleben, Nina L C
AU - Bangsbøll, Susanne
AU - Andersen, Claus Yding
AU - Pedersen, Anette T
AU - Hartwell, Dorthe
AU - Andersen, Anders Nyboe
AU - Løssl, Kristine
AU - Loft, Anne
AU - Freiesleben, Nina L C
AU - Bangsbøll, Susanne
AU - Andersen, Claus Yding
AU - Pedersen, Anette T
AU - Hartwell, Dorthe
AU - Andersen, Anders Nyboe
N1 - Keywords: Adult; Aromatase Inhibitors; CA-125 Antigen; Down-Regulation; Drug Therapy, Combination; Endometriosis; Estrogens; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone; Goserelin; Humans; Nitriles; Pilot Projects; Pregnancy; Pregnancy Outcome; Prospective Studies; Triazoles; Uterine Diseases
PY - 2009/5/1
Y1 - 2009/5/1
N2 - OBJECTIVE: The key enzyme in the biosynthesis of estradiol, aromatase, has been demonstrated within endometriosis. Combined administration of aromatase inhibitor and GnRH-agonist may efficiently suppress estrogen biosynthesis through a combined pituitary, ovarian, peripheral and "in situ" action. The aim of this study was to test the concept of combined down-regulation prior to IVF in patients with endometriomas. STUDY DESIGN: Prospective pilot study in a university-based tertiary fertility clinic including 20 infertile patients with endometriomas undergoing IVF/ICSI. The patients received goserelin 3.6mg sc on treatment Days 1, 28 and 56, and one daily tablet of anastrozole 1mg from Day 1 to Day 69. Controlled ovarian stimulation was initiated from Day 70. Outcome measures were change in endometriomal volume and serum CA125 during down-regulation, standard IVF parameters including pregnancy and delivery rate, and endocrine response. The paired T test and Wilcoxon Signed Rank test were used to analyse paired differences. RESULTS: During the combined down-regulation, the endometriomal volume and the serum CA125 level decreased by 29% (3-39%) and 61% (21-74%), respectively (median (95%CI), P=0.007 and P=0.001). In the IVF/ICSI cycle, the number of oocytes retrieved was 7.5 (6.0-10.0) and the fertilization rate was 0.78 (0.38-1.0). Nine patients (45%) conceived, five (25%) had a clinical pregnancy, and three (15%) delivered healthy children (two singletons and one twin). CONCLUSIONS: Prolonged combined anastrozole and goserelin down-regulation significantly reduces endometriomal volume and serum CA125, and is compatible with IVF pregnancy and delivery. However, a high pregnancy loss was noted.
AB - OBJECTIVE: The key enzyme in the biosynthesis of estradiol, aromatase, has been demonstrated within endometriosis. Combined administration of aromatase inhibitor and GnRH-agonist may efficiently suppress estrogen biosynthesis through a combined pituitary, ovarian, peripheral and "in situ" action. The aim of this study was to test the concept of combined down-regulation prior to IVF in patients with endometriomas. STUDY DESIGN: Prospective pilot study in a university-based tertiary fertility clinic including 20 infertile patients with endometriomas undergoing IVF/ICSI. The patients received goserelin 3.6mg sc on treatment Days 1, 28 and 56, and one daily tablet of anastrozole 1mg from Day 1 to Day 69. Controlled ovarian stimulation was initiated from Day 70. Outcome measures were change in endometriomal volume and serum CA125 during down-regulation, standard IVF parameters including pregnancy and delivery rate, and endocrine response. The paired T test and Wilcoxon Signed Rank test were used to analyse paired differences. RESULTS: During the combined down-regulation, the endometriomal volume and the serum CA125 level decreased by 29% (3-39%) and 61% (21-74%), respectively (median (95%CI), P=0.007 and P=0.001). In the IVF/ICSI cycle, the number of oocytes retrieved was 7.5 (6.0-10.0) and the fertilization rate was 0.78 (0.38-1.0). Nine patients (45%) conceived, five (25%) had a clinical pregnancy, and three (15%) delivered healthy children (two singletons and one twin). CONCLUSIONS: Prolonged combined anastrozole and goserelin down-regulation significantly reduces endometriomal volume and serum CA125, and is compatible with IVF pregnancy and delivery. However, a high pregnancy loss was noted.
U2 - 10.1016/j.ejogrb.2009.02.001
DO - 10.1016/j.ejogrb.2009.02.001
M3 - Journal article
C2 - 19261371
VL - 144
SP - 48
EP - 53
JO - European Journal of Obstetrics, Gynecology and Reproductive Biology
JF - European Journal of Obstetrics, Gynecology and Reproductive Biology
SN - 0301-2115
IS - 1
ER -